ImmunoPrecise Antibodies Ltd.
IPA
$0.4379
$0.01092.55%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -709.93% | 35.98% | 78.04% | -570.41% | -11.73% |
| Total Depreciation and Amortization | -5.22% | 1.66% | -11.55% | 17.35% | -2.68% |
| Total Amortization of Deferred Charges | -3.79% | 6.45% | -51.94% | -- | -- |
| Total Other Non-Cash Items | 23,091.74% | 76.32% | -102.28% | 2,577.80% | -1,586.79% |
| Change in Net Operating Assets | 167.52% | -193.64% | 727.77% | -119.25% | -9.76% |
| Cash from Operations | 48.47% | -23.32% | 31.61% | -154.81% | -5,647.37% |
| Capital Expenditure | -65.55% | 75.22% | 76.87% | -779.62% | 155.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 114.75% | -733.33% |
| Cash from Investing | -65.55% | 75.22% | 76.54% | -2,040.28% | 118.36% |
| Total Debt Issued | -87.47% | -43.82% | -- | -- | -- |
| Total Debt Repaid | 16.22% | -3.30% | -30.46% | 6.21% | -3.87% |
| Issuance of Common Stock | 953.54% | 106.92% | -65.54% | 52.41% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 389.74% | -23.04% | 137.90% | 82.29% | 298.86% |
| Foreign Exchange rate Adjustments | 205.07% | 8.89% | -35.05% | -120.56% | 897.64% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,478.75% | -183.54% | 116.43% | -1,576.06% | 126.24% |